This work was supported by CooperVision
Authors:
Steve Rosinski OD, Jennifer Palombi OD FAAO, Kate Reinhardt
Purpose:
Maintaining satisfaction for advanced presbyopes in multifocal contact lenses (MFCLs) has historically been challenging due to the potential for reduced image quality with higher adds. A multicenter assessment was conducted to assess wearer satisfaction with a new 1-day MFCL at all levels of presbyopia.
Methods:
An observational assessment was conducted at 22 US sites; ECPs fit 186 patients with a new 3-Add MFCL (c3add, somofilcon A, CooperVision, Inc.). Patients were categorized as either low/mid-range (Low-Mid,), with spectacle adds of <+2.00D (n=76), or advanced (Adv) with spectacle adds of ³+2.00D (n=110). Patients completed both an initial dispensing visit and 1-week follow-up. Both groups rated overall vision (OV) and overall wearing satisfaction (OWS) at both visits (scale: 1-10). Data were submitted from June-August 2024. An analysis was performed comparing ratings for Low-Mid vs. Adv groups. For the purpose of analysis, ratings of 7-10 were considered positive experiences. Average ratings by group were also calculated.
Results:
OV and OWS were rated positively by both groups at dispense and follow-up. OV at dispense was rated positively by both (96% positive (Adv) and 93% (Low-Mid)) with average OV ratings being higher overall for Low-Mid than Adv (8.82 vs. 8.41 respectively, p<0.05). OWS at dispense was rated positively 94% of the time by both (average ratings 8.88 (Low-Mid) vs. 8.34 (Adv), p<0.05). At follow-up, both groups rated OVS and OWS positively 93% of the time. Average OV ratings at follow-up were strong for both groups (8.75 (Low-Mid) vs. 8.45 (Adv), p>0.05) as were average OWS ratings (8.64 (Low-Mid) vs 8.53 (Adv), p>0.05).
Conclusion:
c3add supports successful visual outcomes for all levels of presbyopia. This data confirms that ECPs will be able to confidently prescribe c3Add for early to advanced presbyopia with high likelihood of wearer satisfaction when available as a CE marked product under MDR.